WallStreetZenWallStreetZen

NASDAQ: IAM
Iambic Therapeutics Revenue

OverviewEarningsRevenue
DividendOwnership
Iambic Therapeutics revenue was N/A for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2026) ending on Jun 30, 2026 was N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, IAM annual revenue was $9.4M, with 689.4% growth year-over-year.

IAM revenue history

Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%

Be the first to know when IAM announces revenue.

IAM Revenue History By Year

IAM Yearly RevenueIAM RevenueIAM ChangeIAM Revenue Growth
2025-12-31$9.43M$8.23M+689.45%
2024-12-31$1.19MN/AN/A

1 of 1

Iambic Therapeutics Revenue FAQ

What was Iambic Therapeutics's annual revenue growth in the past year?

As of Q4 2026, Iambic Therapeutics's revenue has grown null year over year. Iambic Therapeutics's revenue in the past year totaled N/A.

How much does Iambic Therapeutics make in a year?

Iambic Therapeutics's revenue by year for the past one years is:
  • Iambic Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $9.43 million, a 689.45% increase year over year.

What was Iambic Therapeutics's revenue in 2025?

Iambic Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $9.43 million, a 689.45% increase year over year.

How much does Iambic Therapeutics make in a day?

Based on Iambic Therapeutics annual revenue for the past one years, IAM makes an average of $25,824.66 per day.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.